JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Low, B. C.
Right arrow Articles by Guy, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Low, B. C.
Right arrow Articles by Guy, G. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 275, Issue 19, 14415-14422, May 12, 2000


Evidence for a Novel Cdc42GAP Domain at the Carboxyl Terminus of BNIP-2*

Boon Chuan Low, Kah Tong Seow, and Graeme R. GuyDagger

From the Signal Transduction Laboratory, Institute of Molecular and Cell Biology, 30 Medical Dr., Singapore 117609, Republic of Singapore

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We recently identified BNIP-2, a previously cloned Bcl-2- and E1B-associated protein, as a putative substrate of the FGF receptor tyrosine kinase and showed that it possesses GTPase-activating activity toward Cdc42 despite the lack of homology to previously described catalytic domains of GTPase-activating proteins (GAPs). BNIP-2 contains many arginine residues at the carboxyl terminus, which includes the region of homology to the noncatalytic domain of Cdc42GAP, termed BNIP-2 and Cdc42GAP homology (BCH) domain. Using BNIP-2 glutathione S-transferase recombinants, it was found that its BCH bound Cdc42, and contributed the GAP activity. This domain was predicted to fold into alpha -helical bundles similar to the topology of the catalytic GAP domain of Cdc42GAP. Alignment of exposed arginine residues in this domain helped to identify Arg-235 and Arg-238 as good candidates for catalysis. Arg-238 matched well to the arginine "finger" required for enhanced GTP hydrolysis in homodimerized Cdc42. Site-directed mutagenesis confirmed that an R235K or R238K mutation severely impaired the BNIP-2 GAP activity without affecting its binding to Cdc42. From deletion studies, a region adjacent to the arginine patch (288EYV290 on BNIP-2) and the Switch I and Rho family-specific "Insert" region on Cdc42 are involved in the binding. The results indicate that the BCH domain of BNIP-2 represents a novel GAP domain that employs an arginine patch motif similar to that of the Cdc42-homodimer.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Ras superfamily GTPase proteins act as molecular switches for signal transduction pathways to control cell growth, differentiation, and motility. The Ras superfamily consists of the Ras, Rho, Rab, and Arf families, which are classified according to their sequence similarities and functions (1, 2). These proteins cycle between two guanine-nucleotide bound states, the GTP-bound form, which is active, and the inactive GDP-bound form. Activation occurs as a result of a change in the conformation of discrete "switch regions" in these proteins that allow them to interact with their appropriate effector proteins. The GTP/GDP-regulated proteins possess a low intrinsic activity for hydrolyzing GTP to GDP, but for efficient physiological catalysis, they associate with other proteins, which can enhance their GTPase activity further. These proteins are termed GTPase-activating proteins (GAPs),1 and they have been recognized by conserved amino acid sequence motifs that are characteristic of each family (3).

The Rho subfamily of GTPases, which includes RhoA, RhoB, RhoC, RhoE, RhoG, Rac1, Rac2, Cdc42, and TC10, is involved in various aspects of cytoskeletal organization, cell polarity, and motility (4-6). For example, RhoA is involved in the regulation of stress fibers and focal adhesion formation (7, 8), Rac1 is involved in the formation of lamellipodia and membrane ruffling (9, 10), and Cdc42 is necessary for actin microspikes/filopodia to form (10, 11). Furthermore, all three can activate the Jun amino-terminal kinase, affect the transcription of certain target genes, and regulate the progression of the cell cycle (12, 13). Structural and biochemical studies show that all GAPs, although bearing no close overall sequence homology to each other, exert their effect either by contributing catalytic residues in-trans, by lowering the activation energy for GTP hydrolysis, or by stabilizing the conformation of the inherent GTPases. These mechanisms are employed by 120-kDa RasGAP and the 50-kDa RhoGAP/Cdc42GAP through a highly conserved arginine "finger" catalytic motif and by similar binding topology (3, 14-22). Recently, however, the crystal structure of rna1p, the Schizosaccharomyces pombe ortholog of the mammalian GAP of Ran, revealed a completely different folding pattern that nevertheless contributed to both the catalysis and the stabilization effect on Ran (23).

GAPs have been identified that act preferentially on members of the Rho subfamily. It is interesting to note that two different catalytic domains have been described for GAPs acting on Cdc42. The 50-kDa Cdc42GAP was shown in various crystallographic studies to possess the conventional arginine finger that interacted closely with the Switch I domain from Cdc42 to affect catalysis. The second type of catalytic domain, albeit of unproven physiological relevance, was identified when Cdc42 forms a homodimer. In this circumstance, one molecule can act as a GAP toward the other partner, with catalysis being mediated by a conserved arginine patch in the carboxyl terminus (24, 25).

We have recently shown BNIP-2, a previously cloned Bcl-2 interacting protein, to be a putative substrate of the FGF receptor tyrosine kinase and to bind both Cdc42GAP and Cdc42 when not tyrosine-phosphorylated. Interestingly, BNIP-2 was also shown to possess a "GAP-like" activity toward Cdc42 (26). This protein contains no sequence homology to the canonical catalytic domain of a GAP, but it shares a highly conserved sequence with a region in the amino-terminal, noncatalytic half of Cdc42GAP (26, 27). We wished to determine the sequences in BNIP-2 that were responsible for the binding to Cdc42 and for the catalysis. To do this, we used a combination of site-directed mutagenesis and molecular modeling based on both the known biochemistry and structural topology of the catalytic Cdc42GAP domains. It enabled a hypothetical model to be constructed that formed the basis for the mutational studies. Using this approach, we have found that the BNIP-2 and Cdc42GAP homology (BCH) domain contains the GAP activity in BNIP-2, but not in Cdc42GAP. Within this novel domain, there are two critical arginine residues that are important for conferring the GAP activity. This arginine patch shares reasonable similarity to those residues that mediate the homodimerization-induced GAP activity seen with Cdc42 homodimers (24, 25). Other discrete regions likely to be important for the BNIP-2 and Cdc42 interaction were also identified.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Plasmids-- Full-length cDNA of BNIP-2 was cloned into a hemagglutinin (HA)-tagged expression vector, pXJ40 (Dr. E. Manser, Institute of Molecular and Cell Biology, Singapore), or into pGEX4T-1 vector for producing the GST recombinant protein as described previously (26). pGEX-Cdc42 and pGEX-Cdc42GAP (from Dr. A. Hall, University College London, United Kingdom) were used in making GST fusion proteins or as templates to generate pXJ40HA and pXJ40FLAG constructs. Point mutants of BNIP-2 or Cdc42 were generated by site-directed mutagenesis using the Quick-Change mutagenesis kit (Stratagene), whereas deletion mutants were generated by polymerase chain reaction using specific primers facilitated by restriction sites. All plasmids were purified using a Wizard Miniprep kit (Promega) or a Wizard Maxi/Mega-prep kit followed by ethanol reprecipitation for use in transfection experiments. Clones were confirmed correct by thermal-cycle sequencing using the SequiThermal EXCEL II DNA sequencing kit (Epicentre Technologies) or mapping analyses using restriction enzymes (New England Biolabs). Escherichia coli strain DH5alpha was used as host for propagation of the clones. Reagents used were of analytical grade, and standard protocols for molecular manipulations and media preparations were from Ref. 53.

Cell Culture and Transfection-- Human 293T cells were grown in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum (Hyclone), 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin (all from Sigma) and maintained at 37 °C in a 5% CO2 atmosphere. Cells at 90% confluence in 100-mm plates were transfected for 1 h with 10 µg of indicated plasmid using Tfx-50 cationic lipids according to the manufacturer's instructions (Promega).

Precipitation Experiments and Western Blot Analyses-- Cells were lysed in 1 ml of lysis buffer (50 mM HEPES, pH 7.4, 150 mM sodium chloride, 1.5 mM magnesium chloride, 5 mM EGTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, a mixture of proteases inhibitors (Roche Molecular Biochemicals), and 5 mM sodium orthovanadate). The lysates were directly analyzed as either whole cell lysates (25 µg) or their aliquots (500 µg) were used in affinity precipitation/pulldown experiments with GST-BNIP-2 (5 µg) or GST-Cdc42 (5 µg) that had been preloaded with guanosine 5'-O-3-thiotriphosphate (GTPgamma S) (Sigma) as described previously (26). Samples were run in SDS-PAGE gels and analyzed by Western blotting with HA antibody (Roche Molecular Biochemicals) or FLAG antibody (Sigma).

GAP Assay-- The GAP activity toward Cdc42 was examined by determining the release of 32Pi from the [gamma -32P]GTP prebound to the molecule. GST-Cdc42 (5 µg) still conjugated to the Sepharose beads, were washed twice in Buffer A (50 mM HEPES, pH 7.4, 0.5 mM EDTA), and resuspended in final 10 µl of the same buffer with 5 µCi of [gamma -32P]GTP (6,000 Ci/mmol; New England Nuclear) for 10 min at room temperature. The reaction was terminated by adding 25 mM magnesium chloride. Excess unincorporated radioactive GTP was removed by washing the beads five times in 1 ml of cold Buffer B (50 mM HEPES, pH 7.4, 150 mM sodium chloride, 1.5 mM magnesium chloride, 5 mM EGTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, a mixture of proteases inhibitors, and 5 mM sodium orthovanadate). The beads were finally resuspended in 10 µl of the same buffer. For in vitro GAP assays using proteins expressed in bacteria, eluted recombinants of BNIP-2 (1 µg in 100 µl of Buffer B) were then added to the beads suspension and mixed well. The suspension was quickly centrifuged to collect the beads and incubated at room temperature for the times indicated, and aliquots of the supernatant (10 µl) were then taken for counting in a scintillation counter. For GAP assays involving 293T lysates, cells transfected with BNIP-2 (wild-type or mutants) were lysed in Buffer B. A 20-µl of this lysate (approximately 40 µg of total protein contents) was diluted in 100 µl of Buffer B before added to the GST-Cdc42 beads preloaded with [gamma -32P]GTP and assayed, as described above.

Comparative Molecular Modeling-- Atomic coordinates for the catalytic GAP domain of Cdc42GAP and p85-BH were obtained from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (Protein Data Bank codes 2NGR and 1PBW, respectively) and used as templates for molecular modeling as described previously (28). The alignment between the amino acid sequences of p85-BH, the catalytic GAP domain of Cdc42GAP, BNIP2-BCH, and Cdc42GAP-BCH was obtained using ClustalW1.7 (54) followed by manual adjustment. Using LOOK (Molecular Application Group), the aligned amino acid sequence of BNIP2-BCH was substituted onto the averaged backbone atomic coordinates of p85-BH and Cdc42GAP. The predicted structure was then energy-minimized with a restrained and full conjugate gradient geometry optimization using the molecular modeling software SYBYL 6.4 performed on a UNIX workstation model IRIS/indigo (Silicon Graphics Inc., Mountain View, CA).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

BNIP-2 Binding to Cdc42-- We previously demonstrated that BNIP-2 acts as a GAP protein toward Cdc42, despite its lack of obvious homology to the canonical GAP domain for Cdc42 (26). To gain an insight into the structural/functional relationship between BNIP-2 and Cdc42, we initially set out to identify which regions of BNIP-2 bind to Cdc42. Full-length and various deletion constructs of BNIP-2 were generated as GST recombinants as indicated (Fig. 1A). The full-length protein was arbitrarily dissected into various fragments designated as A, B, BCH, C1, C2, and C3. The C-series fragments encompassed the region of homology between BNIP-2 and Cdc42GAP (26, 27), which we termed BCH domain. The recombinants were expressed in E. coli, purified, and used to precipitate HA-Cdc42 expressed in 293T cells, as described under "Materials and Methods." The precipitated protein was separated by SDS-PAGE followed by Western blotting using HA antibody as the probe. Fig. 1B shows that the recombinant full-length BNIP-2 bound Cdc42 relatively strongly and that this interaction was mainly mediated via the C2 and C3 regions of BNIP-2. Some weaker binding could be seen with fragment A, but no interaction was detectable with the other regions of the molecule. To further demonstrate specificity of binding, two endogenous cellular proteins were assessed for their binding to the fragments of BNIP-2. It can be seen in Fig. 1B (Crk, Lyn, and GST) that neither the Crk adaptor protein nor the Lyn tyrosine kinase bound any of the BNIP-2 fragments. Similarly, no binding by these fragments could be seen when the phosphotyrosine phosphatase SHP-2 was overexpressed in these cells (data not shown). The blot was stripped and reprobed with anti-GST to reveal the integrity of these recombinants and to show equal loading. To further demonstrate that the BCH fragment of BNIP-2 could bind Cdc42, a precipitation experiment was performed. A GST recombinant of BNIP-2 BCH was generated and used to precipitate Cdc42 expressed in 293T cells. Their ability to co-precipitate was compared with the GST recombinants of full-length BNIP-2, Cdc42GAP, and GST beads alone. The results in Fig. 1C show that the BNIP-2 BCH binding to Cdc42 was equivalent to or greater than that by the full-length BNIP-2 and of Cdc42GAP.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 1.   The carboxyl terminus of BNIP-2 binds Cdc42. A, defined are regions of BNIP-2 used in the production of GST recombinants in E. coli as described under "Materials and Methods." B, GST recombinants from A were used to precipitate lysates of 293T cells transfected with expression vector for HA-Cdc42. The associated proteins were separated on SDS-PAGE, blotted, and probed with HA antibody (top panel). The same blot was stripped and sequentially probed for Crk (second panel from top), Lyn (third panel from top) or GST (bottom panel). WCL, whole cell lysates. C, 293T cells were transfected with (+) or without (-) expression vectors for HA-Cdc42 and equal amounts of lysates were used in the precipitation experiment with either GST alone or other GST recombinants as indicated. Bound proteins were separated by SDS-PAGE, blotted, and probed with HA antibody. FL, full-length BNIP-2; BCH, BCH domain of BNIP-2; GAP, catalytic domain of Cdc42GAP.

Molecular Modeling of the BCH Domain-- When BNIP-2 was first cloned and sequenced, it was found to have a domain that was conserved in only one other mammalian protein, an apparently noncatalytic sequence found on the amino-terminal half of Cdc42GAP (27). It could be assumed that BNIP-2 and Cdc42GAP might bind to a common substrate by means of their shared BCH domain. Indeed, multiple sequence alignment was recently presented that suggested that the BCH domain might be a phospholipid-binding domain similar to that of the Saccharomyces cerevisiae phosphatidylinositol transfer protein Sec14p (29). However, there is only a low degree of homology apparent with these two proteins. We demonstrated that the BCH domain mediates both hetero- and homophilic binding of the proteins containing this sequence, which would indicate that the BCH domain is likely to be a protein-protein interaction domain.2 Further alignment studies, however, indicated that the BCH domain was not confined to two known mammalian proteins but has been highly conserved throughout evolution, having been found also in two recently cloned but uncharacterized proteins from Arabidopsis thaliana (Fig. 2A).


View larger version (72K):
[in this window]
[in a new window]
 
Fig. 2.   Modeling of the BCH domain and the putative arginine finger. A, sequence alignment of the BCH domains of BNIP-2 and Cdc42GAP with two putative proteins from A. thaliana containing BCH-like domains. The GenBankTM accession numbers of Arab1 and Arab2 are AL031986 and AC009400, respectively. B, sequence alignment of the BCH domains of BNIP-2 and Cdc42GAP with the catalytic GAP domain of Cdc42GAP and the BH domain of phosphoinositide 3-kinase p85alpha subunit. The conserved alpha -helices corresponding to the GAP domain of Cdc42GAP (19) are depicted as bars on top of the sequences. Numbers corresponding to the residues in each sequence are shown on the right. GenBankTM accession numbers for p85, Cdc42GAP, and BNIP-2 are P27986, Z23024, and U15173, respectively. C, predicted structure of BNIP-2 BCH. The solvent-accessible molecular surfaces are rendered as a field of connected gray dots. Inside the surface is a ribbon representation, with helices colored red, and loops colored light blue. On the surface, yellow dotted lines define the region corresponding to the arginine patch (Arg-235, Arg-236, and Arg-238) and the region containing 288EYV290. The side chains of these residues are shown as spacefill and colored blue for basic, yellow for polar, and gray for hydrophobic residues. D, alignment of the arginine patch of BCH domain with the putative arginine finger motifs of Rho. Asterisks indicate the Rho proteins that have the active arginine residues important for their GAP activity (arrow). Black, dark gray, and light gray shading refers to 100, 80, and 60% sequence similarity, respectively. Hs, Homo sapiens; Sc, S. cerevisiae. Numbers refer to the residue positions of BNIP-2.

Because the BCH domain is found as a discrete homologous protein domain highly conserved in sequence throughout evolution, it is plausible that the BCH domain of BNIP-2 could form a functional and structural domain with GAP activity toward Cdc42. In order to perform mutational experiments to address this possibility, we need to know what residues are most likely to be involved in the catalysis and binding. As we currently lack a crystal structure of the complex, we decided to make some testable assumptions using molecular modeling techniques.

Most GAPs have well defined structure and substrate specificities, as exemplified by RasGAP, RanGAP, and RhoGAP acting only on Ras, Ran, and Rho respectively. To date, structures of two RhoGAP domains binding to Cdc42 have been identified, one for the catalytic GAP domain of Cdc42GAP (16, 19, 21) and the other one for the BH domain of the phosphoinositide 3-kinase p85alpha subunit (30). Although it binds to Cdc42, the BH domain fails to act as a functional GAP for Cdc42. We therefore set out to test whether the BCH domain, which also acts on Cdc42, would have a structure similar to these domains. To test this hypothesis, we predicted and modeled the tertiary structure of the BCH domain. First, we aligned the BCH domains of BNIP-2 and Cdc42GAP to the canonical GAP domain of Cdc42GAP and the BH domain of p85alpha . Both the GAP domain of Cdc42GAP and the BH domain of p85 alpha  have similar structural folds (16, 19, 21, and 30). The alignment shows considerable conservation in regions corresponding to the secondary structural elements (alpha -helices) of the GAP domain or the p85-BH domain (Fig. 2B). We then used the structures of the Cdc42GAP "GAP" domain and the p85-BH domain as structural templates to model the BCH domain using the homology modeling techniques described under "Materials and Methods." The predicted structure (Fig. 2C) was used as a basis for the design of site-directed mutagenesis and deletion experiments. Our assumption was that if the BCH domain folds into the predicted GAP-like structure and binds to Cdc42 in a manner similar to the catalytic GAP domain, we could use the model to facilitate the identification of BCH residues and regions involved in (a) GAP catalytic activity and (b) binding to Cdc42.

Identification of Candidate Residues Important for BNIP-2 GAP Activity-- Based on the model above, we first sought to identify candidate residues that might be important in mediating BNIP-2 GAP activity. We assumed that these residues would fulfill the criteria as listed below with respect to the known structure and the biochemistry of the GAP domains of Cdc42GAP. The two GAP domains that have been described achieve catalysis either via an arginine finger (Cdc42GAP) or via a conserved arginine patch (found in Cdc42, Rac1, RhoG, and RhoC homodimers). Both arginine-containing sequences must be positioned on the outside of the three-dimensional structure of the protein. According to our model, there was no obvious region on BNIP-2 that corresponded to the reactive arginine finger Arg-305 of Cdc42GAP. We noted, however, a polybasic patch prominently displayed on the exterior of the protein model corresponding to a region containing Arg-235, Arg-236, and Arg-238 (as indicated in Fig. 2C). Somewhat surprisingly, this region matches a reactive arginine motif recently identified in the human Cdc42, Rac1, RhoC, and RhoG homodimers (Fig. 2D). Although not required for the formation of dimers, this polybasic patch in these members of the Rho subfamily was identified to be responsible for the GAP-like activity when homodimers were formed (24, 25). Of particular interest is that in this local alignment, the Arg-238 in BNIP-2 aligns to the critical arginine residue (Fig. 2D, arrow) that is indispensable for their GAP activities. It is notable that this arginine residue is absent from those members of the Rho family (and the BCH domain of Cdc42GAP) that lack the GAP activity.

We next mutated individual arginine residues to lysine to form R235K, R236K, and R238K and tested whether they contribute to the GAP-like catalytic activity of BNIP-2 on Cdc42. Each of these mutations was introduced into the full-length BNIP-2 and expressed in vivo in mammalian 293T cells. Lysates from control and transfected cells were then tested for their ability to catalyze the GTP-hydrolysis of GST-Cdc42 preloaded with [gamma -32P]GTP, as described under "Materials and Methods." Fig. 3A shows that the intrinsic GTPase activity of Cdc42 followed a linear time course over 30 min and showed minimal catalytic activity under the conditions studied. This activity was enhanced over 10-fold in the presence of wild-type BNIP-2. Interestingly, mutations of the prime candidate arginine, Arg-238, as well as Arg-235 markedly reduced the enhanced GAP activity toward Cdc42. In comparison, the R236K mutant showed a GAP-like activity that was 50% of that of wild-type BNIP-2. We also generated corresponding mutants as full-length GST recombinants in bacteria to test their effects on GTP hydrolysis in vitro. Results similar to those in Fig. 3A were obtained, verifying that these BNIP-2 mutants had significantly lost the ability to enhance the GTP hydrolysis of Cdc42 (data not shown).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of arginine-to-lysine mutations on the GAP activity of BNIP-2 expressed in vivo. A, 293T cells were transfected with control vector (open circles) or with expression vectors for the full-length HA-BNIP-2: wild-type (filled circles), R235K (filled triangles), R236K (filled squares), and R238K (open triangles). Lysates were used in assays with recombinant Cdc42 that was preloaded with radiolabeled GTP as described under "Materials and Methods." B, lysates from A were used in a pulldown experiment with equal amounts of GST-Cdc42 preloaded with GTPgamma S, and bound proteins were separated by SDS-PAGE, blotted, and probed with HA antibody (upper panel). The same blot was stripped and probed for GST to demonstrate equal loading (lower panel) WT, wild-type.

Although each of these point mutations showed varying inhibitory effects on the rates of GTP-hydrolysis, none was completely inactive toward Cdc42, consistent with the notion that multiple residues are involved in the GAP activity. To ensure that the loss in the GAP activity by these mutants was not simply due to a loss of binding to the partner protein or by misfolding of the recombinant protein, we used GST-Cdc42 to test the binding to these mutants from the cell lysates in precipitation experiments. Fig. 3B shows that each of the mutants was soluble and that they had equal levels of expression in 293T cells. When subjected to precipitation experiments, each of the point-mutants exhibited an apparently equal affinity to the GTP-loaded GST-Cdc42. This indicates that the overall structural integrity of the BNIP-2 point mutants was maintained and that these putative catalytic arginine residues were unlikely to be directly involved in binding.

To further confirm that the BCH domain of BNIP-2 itself can fold separately and act effectively as a GAP, various BCH GST recombinants with or without the above point mutations were generated, purified, and used in GAP assays (Fig. 4A). Consistent with the full-length studies involving either BNIP-2 expressed in vivo, or in vitro, the recombinant BCH of BNIP-2 alone could stimulate the rate of GTP hydrolysis of Cdc42 by 10-fold. Again, the GAP-like activity associated with the BNIP-2 BCH domain was severely impaired by the R238K and R235K mutants and less severely by the R236K mutant. In contrast, the homologous BCH domain of Cdc42GAP was completely inactive toward Cdc42, although it can also bind Cdc42 (data not shown). To ensure that the integrity of these bacterially expressed recombinants remained intact, they were tested for binding HA-Cdc42 in precipitation experiments (Fig. 4B). The results show that none of the binding to Cdc42 had been compromised and again demonstrate that these residues are important in the catalysis but not for the binding.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 4.   The BCH domain of BNIP-2 confers GAP activity. A, GST recombinants for the BCH domain of BNIP-2 (either as the wild-type (WT) or as mutant R235K, R236K, or R238K) were produced, eluted, and used to determine their GAP effect on the GTP hydrolysis of Cdc42 preloaded with radiolabeled GTP as described under "Materials and Methods." The activity was expressed as the fold increase over the control using GST alone. Results are means ± S.D. of three replicate determinations. B, 293T cells were transfected with expression vector for HA-Cdc42, and equal amounts of lysates were used in precipitation experiments using the GST recombinants from A. Bound proteins were separated by SDS-PAGE, blotted, and probed with HA antibody.

Binding Regions within BCH and Cdc42-- Most effectors/regulators of Cdc42 bind to the Switch I region (effector binding domain) and/or the Rho family-specific "Insert" region (31). We had previously generated Cdc42 recombinants with the amino-terminal half containing the Switch I and Switch II regions, and the carboxyl-terminal half of the Cdc42 containing the Insert region. We found that either half of the molecule could bind to BNIP-2, suggesting that there are multiple sites of binding on Cdc42 for BNIP-2 (data not shown). In order to delineate the sites of interaction further, small deletion mutants of the Switch I (amino acids 32-40; Delta SI), Switch II (amino acids 60-70; Delta SII), or the Insert region (amino acids 89-94; Delta Ins) were generated. These deletion mutants were then used to test for binding to either the wild-type BNIP-2 or the BNIP-2 deletion mutant, Delta T, that is devoid of residues 288EYV290. This region is located on the outer surface and is potentially involved in binding Cdc42 as predicted from our model above (Fig. 2C). As a control, we deleted the 235RRLRK239 region (Delta R) in BNIP-2, assumed by modeling and experimental data (shown above) to be important for catalysis and not for binding.

To test the various interactions, the wild-type or deletion constructs of HA-BNIP-2 (Delta R or Delta T) were expressed in 293T cells, and the lysates were subjected to precipitation experiments with GTPgamma S-bound GST-Cdc42, either as the wild-type or with deletions in the Switch I, Switch II, or Insert region. The results in Fig. 5A show that each of the HA-BNIP-2 wild-type or mutants was expressed equally well in 293T cells (see WCL), and none of them bound the controls with GST beads alone. The binding by the wild-type BNIP-2 was not significantly affected by any single deletion on Cdc42 (Fig. 5A, compare results in lane 1). This confirmed our previous observation that there exist multiple sites of interaction on Cdc42 for BNIP-2. Similar results were seen when the proposed catalytic domain of BNIP-2 was deleted (lane 2). However, when the BNIP-2 Delta T mutant was used as the target (lane 3), there was nearly a 50% loss in its binding to the Cdc42 mutants lacking either the Switch I region or the Insert region. No effect was seen in the binding of this Delta T mutant to the wild-type Cdc42 or its Switch II deletion mutant. The apparent synergistic effect that deletions of region T have with Switch I or the Insert would be consistent with the notion that region T does not interact directly with either the Switch I or the Insert. A similar degree in the loss of binding would have been seen by either single or combined deletions of these constructs if region T was binding to either the Switch I or Insert. This means that the Switch I and the Insert region of Cdc42 would both contribute to the binding to two distinct but unknown regions on BNIP-2, whereas the region T (encompassing 288EYV290) on BNIP-2 would represent another site of interaction with other region(s) of Cdc42.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 5.   Binding regions on Cdc42 and BNIP-2. A, 293T cells were transfected with expression vectors for HA-BNIP-2 either as the wild-type (lane 1), deletion mutant Delta R (lane 2), or deletion mutant Delta T (lane 3) as described in text. Lysates were then used in precipitation experiments using GST-Cdc42, wild-type (WT), or deletions in the regions of Switch I (Delta SI), Switch II (Delta SII), or the Rho family-specific Insert (Delta Ins), all of which were preloaded with GTPgamma S prior to precipitation experiments as described under "Materials and Methods." Bound proteins were separated in SDS-PAGE, blotted, and probed with HA antibody. Aliquots of lysates from A were analyzed for the equal expression of HA-BNIP-2 proteins by HA Western analysis, indicated as whole cell lysates (WCL), and also tested for nonspecific binding to the GST beads alone. B, 293T cells were transfected with expression vector for FLAG-Cdc42GAP, and equal aliquots of lysates were used in precipitation experiments using the GST-Cdc42 wild-type (WT), Delta SI, Delta SII, or Delta Ins preloaded with GTPgamma S, as in A. Bound proteins were separated in SDS-PAGE, blotted, and probed with FLAG antibody. C, 293T cells were transfected with expression vectors for HA-Cdc42 as either the wild-type (lanes 1), G12V mutant (lanes 2), or T17N mutant (lanes 3). Lysates were used in precipitation experiments using GST recombinants of either the full-length BNIP-2 (FL) or the BCH domain of BNIP-2 as indicated. Bound proteins were separated by SDS-PAGE, blotted and probed with HA antibody. Aliquots of whole cell lysates were probed with HA antibody to determine the equal expression of the HA-tagged wild-type or mutant Cdc42.

Contrary to the requirement for multiple regions of binding to Cdc42 by BNIP-2, as demonstrated above, deletion of the Switch I region alone in the GTPgamma S-bound form of Cdc42 could reduce its binding to Cdc42GAP by two-thirds, whereas deletions of the Switch II or the Insert region had no effect on the binding (Fig. 5B). The direct involvement of the Switch I but not the Insert region of Cdc42 in binding Cdc42GAP is consistent with the crystallographic structure of the complex (15). However, we were surprised that deletion of the Switch II region had minimal effects on Cdc42 binding to Cdc42GAP, when similar studies had shown it to be a likely interacting sequence (15).

It was shown previously that in the Ras·RasGAP complex (32) the Gly-12 residue in the Switch I region of the GTPase contacts part of the GAP closely. Mutation of this residue to valine (G12V) significantly reduced the binding of RasGAP to Ras (32, 33). We hypothesized that the BCH domain of BNIP-2 would have a similar recognition profile. To test this hypothesis, HA-Cdc42 constructs were expressed in 293T cells either as the wild-type, G12V, or T17N point mutations, and each was subjected to precipitation experiments using GST recombinants of either the full-length BNIP-2 or the BCH domain of BNIP-2. The results in Fig. 5C show that the full-length BNIP-2 and the BCH domain of BNIP-2 recognize wild-type Cdc42 readily and in each case increased binding to the T17N mutant was apparent. However, their binding to the G12V mutant was greatly diminished.

The loss of BCH binding to the G12V mutant is analogous to the decrease of RasGAP binding to the G12V mutant of Ras. In the latter case, the mutation did not change the overall structure of the molecule, but it resulted in a reduced flexibility in the loop 4 region for proper conformational change, particularly around the Gly-60 and Gln-61 residues, both of which are involved in gamma -phosphate binding and the enzymatic reaction (32). These results indicate that the BCH domain of BNIP-2 assumes a high degree of sensitivity toward some of the conformational changes in Cdc42 in a manner similar but perhaps not identical to that of the canonical GAPs.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We have identified several arginines as key residues within the BNIP-2 BCH domain that are responsible for the GAP activity of the protein. This region containing the arginines bears no similarity to the arginine motifs employed by the "cradle-fold" structural topology in the RasGAP or Cdc42GAP/RhoGAP catalytic structures (3, 14-22) or to the leucine repeat folds of RanGAP binding to Ran (23). It does, however, show a striking similarity to the polybasic carboxyl terminus of Cdc42. Although not required for the formation of dimers, this polybasic patch in Cdc42 was identified to be responsible for its GAP-like activity when homodimers are formed (24, 25). Of particular interest is that in this local alignment, the Arg-238 in BNIP-2 matches the critical arginine residue that is indispensable for the homodimer-enhanced GAP activity. In those members of the Rho subfamily that fail to display GAP activity when homodimerized, i.e. RhoA and the yeast form of Cdc42 (25), this arginine is absent, as it is from the BCH domain of Cdc42GAP, which is also catalytically inactive (Fig. 2D). Although it lacks GAP activity, the BCH domain of Cdc42GAP can still bind to Cdc42 (data not shown).

Despite the varying degrees of the loss of GAP activity displayed by the R238K, R235K, and R236K mutants, BNIP-2 still retains its ability to bind Cdc42, indicating that these residues are not involved in the binding to Cdc42. The conserved arginine fingers in the GAP domains of Cdc42GAP (34) or RasGAP (18, 35) have all been shown to be important for catalysis and not for binding to their respective partners. In both Cdc42GAP and RasGAPs, catalytic enhancement is likely to be the result of stabilization of the conformation most complementary to the transition state and from ground state destabilization (3, 14-22, 34-37). It is most likely that the reactive "arginine patch" in BNIP-2 would confer one or more of the residues in-trans for the catalysis. In this regard, we observed that Arg-235 and Arg-238 are potent residues. The current work utilizes semiquantitative measurements to demonstrate the involvement of such arginine fingers in the BCH domain of BNIP-2. The actual relative contribution from each arginine residue or combination of arginines 235, 236, and 238 awaits a more thorough kinetic determination.

In some of the most efficient phosphoryl-transferring enzymes, such as adenylate kinase and uridylate kinase (38, 39), several arginine residues are located in the active sites and they catalyze the reaction by stabilizing developing negative charges in the transition state. Although the involvement of multiple neighboring polybasic residues had not been tested in the similar arginine patches in Cdc42 and other Rho family members, it is tempting to speculate that these tandem arginine residues in BNIP-2 would provide a positive-charge interface to stabilize the negative charges that develop during the transition state of GTP hydrolysis in Cdc42. In Cdc42GAP, the Arg-305 within the classical GAP domain has been identified both structurally and biochemically as the key catalytic residue in promoting GTP hydrolysis in Cdc42. It does not account, however, for the full GAP activity. Recently, its adjacent arginine residue, Arg-306, was identified to be necessary to further augment its GAP activity (40). Similarly, the p120-RasGAP and the other RasGAP, neurofibromin NF1, both require at least the input of Arg-789 and Arg-903 (for p120-RasGAP (17, 41)) or Arg-1276 and Arg-1391 (for NF1 (42)) for optimal catalysis. Therefore, it appears that although the BCH domain of BNIP-2 shows no clear sequence homology to any of these molecules, it too could utilize the same means to facilitate GTP hydrolysis by Cdc42.

Recently, evidence has begun accumulating that demonstrates that various GTPases are the preferred eukaryotic substrates of diverse bacterial toxins and exoenzymes (43-45). Several of these bacterial products have been shown to interfere with Rho family GTPase activity by means of chemical modifications on important residues (46, 47) or increasing the lifetime of the active GTP-bound form of the Rho proteins (48). Recently, the amino-terminal domain of Pseudomonas aeruginosa exoenzyme S was shown to activate the GTPase activity of Rho, Rac, and Cdc42 (45). It was interesting to note that the catalytic domain on this protein had no strong sequence homology to any canonical Rho-GAPs, thus providing evidence that dissimilar primary sequences are capable of performing a similar catalytic function when folded in the appropriate conformation.

Based on modeling, we attempted to identify the candidate regions for interaction between BNIP-2 and Cdc42. We observed that at least three sites on each protein are involved in interprotein binding. We showed that the region 288EYV290 on BNIP-2 together with the Switch I or Insert region of Cdc42 synergistically caused a 50% loss in binding, suggesting that they include at least three of these binding sites. These data differ from those derived from studies on the "classical" GAP domain of Cdc42GAP, in which deletion of the Switch I region on Cdc42 alone was already sufficient to markedly reduce the binding to this domain.

More than 10 direct interacting partners of Cdc42 have been identified to date (Ref. 26 and references therein). It remains a major issue as to how the incoming signals determine the specificity of functional coupling between this molecule and its effectors/regulators. Recently, Li et al. (49) utilized a mutational and chimeric approach and mapped unique regions on Cdc42 responsible for binding to three different target proteins. They showed that the Switch I and the immediate neighboring region on Cdc42 contain all the necessary determinants for PAK1 binding, whereas WASP and IQGAP1 did not bind the same sequence. Two distantly located regions on Cdc42, residues 155-184 and residues 83-120, constitute the WASP- and IQGAP1-binding regions, respectively. Furthermore, it was shown that the Rho family-unique Insert region of Cdc42 is dispensable for PAK1 and WASP binding but is required for high affinity binding by IQGAP1. Recently, solution structures for the complex of Cdc42 binding to ACK (50) and Cdc42 binding to WASP (51) have highlighted the involvement of unique regions within Cdc42 and the respective effectors in mediating the specificity in the binding. Our results show that the binding of BNIP-2 to Cdc42 was mainly mediated by the Switch I and the Insert region. It will be interesting to test how BNIP-2 affects the binding of other effectors to Cdc42 and to what extent this would affect cellular functions. We have recently shown that BNIP-2, when tyrosine-phosphorylated, failed to bind Cdc42 (26). This phosphorylation could conceivably act as an additional switch to regulate the formation/dissociation of the complex.

Based on our model, the BCH domain of BNIP-2 was predicted to display folding similar to that of the classical GAP domain of Cdc42GAP. Nevertheless, the refined structure is likely to be different from that of the predicted structure. As noted previously, BNIP-2 binds equally well to each form of Cdc42, whereas Cdc42GAP recognizes only the GDP or GTP-bound form of Cdc42 (26, 52). This difference in binding selectivity is further supported by our observations that a deletion in the Switch I region of Cdc42 caused severe loss of binding to Cdc42GAP but not to BNIP-2, suggesting that this region alone is not sufficient to confer tight binding to BNIP-2.

The identification of the BCH domain as a binding domain for Cdc42 in BNIP-2 and Cdc42GAP has further implications. Whereas the BCH domain of BNIP-2 acts as a GAP, the corresponding region in Cdc42GAP does not, partly because of its lack of Arg-236 and Arg-238 (see Fig. 2D). This raises an interesting issue as to what role this region may play in the physiological function of Cdc42GAP. Most previous biochemical and functional studies involving the interaction of various GAPs with their binding partners were performed using the minimal GAP domains, and any potential regulation via the non-GAP domains would have been overlooked. We have evidence that suggests that the BCH domain is also involved in homophilic and heterophilic interactions involving BNIP-2 and Cdc42GAP. The discrete regions that mediate these interactions are different from those involved in the binding to Cdc42.2 It therefore seems likely that, because of this binding specificity, this domain will have some regulatory function.

In conclusion, our present work has shown that the BCH domain of BNIP-2 define a new catalytic GAP domain that contains an arginine patch similar to that found in certain members of the Rho subfamily when they form homodimers. Although the actual mechanism of GAP catalysis by either BNIP-2 or Cdc42 has yet to be determined by x-ray or NMR structural analyses, current evidence suggests that strategically placed arginine residues may represent GAP domains in different primary sequences and tertiary structures. This notion is supported by the recent identification of the arginine finger of rna1p/RanGAP present in a novel folding structure that is mediated by leucine-rich repeats (23).

    ACKNOWLEDGEMENTS

We thank Dr. Catherine Pallen, Dr. Permeen Yusoff, and Jormay Lim for constructive criticism and help in reading the manuscript. We are also grateful to Dr. Alan Hall for the generous donation of materials.

    FOOTNOTES

* This work was supported by the Institute of Molecular and Cell Biology, National University of Singapore.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 65-874-3737; Fax: 65-779-1117; E-mail: mcbgg@imcb.nus.edu.sg.

2 B. C. Low, K. T. Seow, and Graeme R. Guy, manuscript in preparation.

    ABBREVIATIONS

The abbreviations used are: GAP, GTPase-activating protein; BCH, BNIP-2 and Cdc42GAP homology; BH, breakpoint cluster region homology; GST, glutathione S-transferase; GTPgamma S, guanosine 5'-3-O-(thio)triphosphate; HA, hemagglutinin; PAGE, polyacrylamide gel electrophoresis.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Lamarche, N., and Hall, A. (1994) Trends Genet. 10, 436-440[CrossRef][Medline] [Order article via Infotrieve]
2. Kjoller, L., and Hall, A. (1999) Exp. Cell Res. 253, 166-179[CrossRef][Medline] [Order article via Infotrieve]
3. Scheffzek, K., Ahmadian, M. R., and Wittinghofer, A. (1998) Trends Biochem. Sci. 23, 257-262[CrossRef][Medline] [Order article via Infotrieve]
4. Chant, J., and Stowers, L. (1995) Cell 81, 1-4[CrossRef][Medline] [Order article via Infotrieve]
5. Hall, A. (1998) Science 279, 509-514[Abstract/Free Full Text]
6. Hall, A. (1999) Br. J. Cancer 80 Suppl 1, 25-27
7. Chardin, P., Boquet, P., Modaule, P., Popoff, M. R., Rubin, E. J., and Gill, D. M. (1989) EMBO J. 8, 1087-1092[Medline] [Order article via Infotrieve]
8. Paterson, H. F., Self, A. J., Garrett, M. D., Just, I., Aktories, K., and Hall, A. (1990) J. Cell Biol. 111, 1001-1009[Abstract/Free Full Text]
9. Waterman-Storer, C. M., Worthylake, R. A., Liu, B. P., Burridge, K., and Salmon, E. D. (1999) Nat. Cell Biol. 1, 45-50[CrossRef][Medline] [Order article via Infotrieve]
10. Kozma, R., Ahmed, S., Best, A., and Lim, L. (1995) Mol. Cell. Biol. 15, 1942-1952[Abstract]
11. Nobes, C. D., and Hall, A. (1995) Cell 81, 53-62[CrossRef][Medline] [Order article via Infotrieve]
12. Minden, A., Lin, A., Claret, F. X., Abo, A., and Karin, M. (1995) Cell 81, 1147-57[CrossRef][Medline] [Order article via Infotrieve]
13. Aspenstrom, P. (1999) Curr. Opin. Cell Biol. 11, 95-102[CrossRef][Medline] [Order article via Infotrieve]
14. Sprang, S. R. (1997) Curr. Opin. Struct. Biol. 7, 849-856[CrossRef][Medline] [Order article via Infotrieve]
15. Rittinger, K., Walker, P. A., Eccleston, J. F., Nurmahomed, K., Owen, D., Laue, E., Gamblin, S. J., and Smerdon, S. J. (1997) Nature 388, 693-697[CrossRef][Medline] [Order article via Infotrieve]
16. Nassar, N., Hoffman, G. R., Manor, D., Clardy, J. C., and Cerione, R. A. (1998) Nat. Struct. Biol. 5, 1047-1052[CrossRef][Medline] [Order article via Infotrieve]
17. Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmuller, L., Lautwein, A., Schmitz, F., and Wittinghofer, A. (1997) Science 277, 333-338[Abstract/Free Full Text]
18. Ahmadian, M. R., Stege, P., Scheffzek, K., and Wittinghofer, A. (1997) Nat. Struct. Biol. 4, 686-689[CrossRef][Medline] [Order article via Infotrieve]
19. Barrett, T., Xiao, B., Dodson, E. J., Dodson, G., Ludbrook, S. B., Nurmahomed, K., Gamblin, S. J., Musacchio, A., Smerdon, S. J., and Eccleston, J. F. (1997) Nature 385, 458-461[CrossRef][Medline] [Order article via Infotrieve]
20. Bax, B. (1998) Nature 392, 447-448[Medline] [Order article via Infotrieve]
21. Rittinger, K., Taylor, W. R., Smerdon, S. J., and Gamblin, S. J. (1998) Nature 392, 448-449[CrossRef][Medline] [Order article via Infotrieve]
22. Calmels, T. P., Callebaut, I., Leger, I., Durand, P., Bril, A., Mornon, J. P., and Souchet, M. (1998) FEBS Lett. 426, 205-211[CrossRef][Medline] [Order article via Infotrieve]
23. Hillig, R. C., Renault, L., Vetter, I. R., Drell, T., IV, Wittinghofer, A., and Becker, J. (1999) Mol. Cell 3, 781-791[CrossRef][Medline] [Order article via Infotrieve]
24. Zhang, B., and Zheng, Y. (1998) J. Biol. Chem. 273, 25728-25733[Abstract/Free Full Text]
25. Zhang, B., Zhang, Y., Collins, C. C., Johnson, D. I., and Zheng, Y. (1999) J. Biol. Chem. 274, 2609-2612[Abstract/Free Full Text]
26. Low, B. C., Lim, Y. P., Lim, J., Wong, E. S. M., and Guy, G. R. (1999) J. Biol. Chem. 274, 33123-33130[Abstract/Free Full Text]
27. Boyd, J. M., Malstrom, S., Subramanian, T., Venkatesh, L. K., Schaeper, U., Elangovan, B., D'Sa-Eipper, C., and Chinnadurai, G. (1994) Cell 79, 341-351[CrossRef][Medline] [Order article via Infotrieve]
28. Chen, C., Seow, K. T., Guo, K., Yaw, L. P., and Lin, S.-C. (1999) J. Biol. Chem. 274, 19799-197806[Abstract/Free Full Text]
29. Aravind, L., Neuwald, A. F., and Ponting, C. P. (1999) Curr. Biol. 9, 195-197
30. Musacchio, A., Cantley, L. C., and Harrison, S. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 10, 14373-14378
31. Feltham, J. L., Dotsch, V., Raza, S., Manor, D., Cerione, R. A., Sutcliffe, M. J., Wagner, G., and Oswald, R. E. (1997) Biochemistry 36, 8755-8766[CrossRef][Medline] [Order article via Infotrieve]
32. Krengel, U., Schlichting, L., Scherer, A., Schumann, R., Frech, M., John, J., Kabsch, W., Pai, E. F., and Wittinghofer, A. (1990) Cell 62, 539-548[CrossRef][Medline] [Order article via Infotrieve]
33. Al-Mulla, F., Milner-White, E. J., Going, J. J., and Birnie, G. D. (1999) J. Pathol. 187, 433-438[CrossRef][Medline] [Order article via Infotrieve]
34. Graham, D. L., Eccleston, J. F., and Lowe, P. N. (1999) Biochemistry 38, 985-991[CrossRef][Medline] [Order article via Infotrieve]
35. Geyer, M., Schweins, T., Herrmann, C., Prisner, T., Wittinghofe, A., and Kalbitzer, H. R. (1996) Biochemistry 35, 10308-10320[CrossRef][Medline] [Order article via Infotrieve]
36. Ahmed, S., Lee, J., Wen, L. P., Zhao, Z., Ho, J., Best, A., Kozma, R., and Lim, L. (1994) J. Biol. Chem. 269, 17642-17648[Abstract/Free Full Text]
37. Morcos, P., Thapar, N., Tusneem, N., Stacey, D., and Tamanoi, F. (1996) Mol. Cell. Biol. 16, 2496-2503[Abstract]
38. Abele, U., and Schulz, G. E. (1995) Protein Sci. 4, 1262-1271[Abstract]
39. Scheffzek, K., Kliche, W., Wiesmuller, L., and Reinstein, J. (1996) Biochemistry 35, 9716-9727[CrossRef][Medline] [Order article via Infotrieve]
40. Leonard, D. A., Lin, R., Cerione, R. A., and Manor, D. (1998) J. Biol. Chem. 273, 16210-16215[Abstract/Free Full Text]
41. Scheffzek, K., Lautwein, A., Kabsch, W., Ahmadian, M. R., and Wittinghofer, A. (1996) Nature 384, 591-596[CrossRef][Medline] [Order article via Infotrieve]
42. Sermon, B. A., Lowe, P. N., Strom, M., and Eccleston, J. F. (1998) J. Biol. Chem. 273, 9480-9485[Abstract/Free Full Text]
43. Aktories, K. (1997) Trends Microbiol. 5, 282-288[CrossRef][Medline] [Order article via Infotrieve]
44. Fu, Y., and Galan, J. E. (1999) Nature 401, 293-297[CrossRef][Medline] [Order article via Infotrieve]
45. Goehring, U.-M., Schmidt, G., Pederson, K. J., Aktories, K., and Barbieri, J. T. (1999) J. Biol. Chem. 274, 36369-36372[Abstract/Free Full Text]
46. Sekine, A., Fujiwara, M., and Narimuya, M. (1989) J. Biol. Chem. 264, 8602-8605[Abstract/Free Full Text]
47. Just, I., Selzer, J., Wilm, M., von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) Nature 375, 500-503[CrossRef][Medline] [Order article via Infotrieve]
48. Horiguchi, Y., Inoue, N., Masuda, M., Kashimoto, T., Katahira, J., Sugimoto, N., and Matsuda, M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11623-11626[Abstract/Free Full Text]
49. Li, R., Debreceni, B., Jia, B., Gao, Y., Tigyi, G., and Zheng, Y. (1999) J. Biol. Chem. 274, 29648-27654[Abstract/Free Full Text]
50. Mott, H. R., Owen, D., Nietlispach, D., Lowe, P. N., Manser, E., Lim, L., and Laue, E. D. (1999) Nature 399, 384-388[CrossRef][Medline] [Order article via Infotrieve]
51. Abdul-Manan, N., Aghazadeh, B., Liu, G. A., Majumdar, A., Ouerfelli, O., Siminovitch, K. A., and Rosen, M. K. (1999) Nature 399, 379-383[CrossRef][Medline] [Order article via Infotrieve]
52. Lancaster, C. A., Taylor-Harris, P. M., Self, A. J., Brill, S., van Erp, H. E., and Hall, A. (1994) J. Biol. Chem. 269, 1137-1142[Abstract/Free Full Text]
53. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , pp. 1.53-1.85, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
54. Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994) Nucleic Acids Res. 22, 4673-4680[Abstract/Free Full Text]


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Cell Sci.Home page
U. J. K. Soh and B. C. Low
BNIP2 extra long inhibits RhoA and cellular transformation by Lbc RhoGEF via its BCH domain
J. Cell Sci., May 15, 2008; 121(10): 1739 - 1749.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
J. P. Buschdorf, L. Li Chew, B. Zhang, Q. Cao, F.-Y. Liang, Y.-C. Liou, Y. T. Zhou, and B. C. Low
Brain-specific BNIP-2-homology protein Caytaxin relocalises glutaminase to neurite terminals and reduces glutamate levels.
J. Cell Sci., August 15, 2006; 119(Pt 16): 3337 - 3350.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
B. L. Lua and B. C. Low
Activation of EGF receptor endocytosis and ERK1/2 signaling by BPGAP1 requires direct interaction with EEN/endophilin II and a functional RhoGAP domain
J. Cell Sci., June 15, 2005; 118(12): 2707 - 2721.
[Abstract] [Full Text] [PDF]